MetaCap

Anixa Biosciences (ANIX) vs Upstream Bio (UPB)

Head-to-head comparison of performance, valuation, growth, profitability and dividends. Prices delayed 15 minutes; data as of Nov 22, 2026.

Summary

Anixa Biosciences (ANIX) has outperformed Upstream Bio (UPB) over the past year, losing 43.8% versus a loss of 93.8%. Upstream Bio is the larger company by market cap ($87.2 million vs $84.8 million), about 1.0 times the size.

Summary generated from market data by MetaCap's automated system. Methodology

Relative performance

ANIX-43.78%UPB-93.78%
+34%-33%-100%
Nov 21, 20251 yearNov 20, 2026
ANIX-18.94%UPB-92.77%
+67%-17%-100%
Oct 7, 20245 yearsNov 16, 2026

Percent change in share price from the first common trading day shown; excludes dividends.

Head-to-head

ANIX versus UPB key metrics
MetricANIXUPB
Share price$2.44$1.59
Market cap$84.82M$87.15M
1-day change-6.15%-20.50%
YTD return-21.79%-94.14%
1-year return-43.78%-93.78%
5-year return-38.69%—
EPS (TTM)$-0.32$-3.01
Dividend yield0.00%0.00%
Annual dividend$0.00$0.00
Revenue (latest FY)—$2.85M
Revenue growth (YoY)—+20.42%
Net income (latest FY)$-10.93M$-143.44M
Operating margin—-5618.82%
Net margin—-5026.03%
52-week high$5.46$33.68
52-week low$2.32$1.56
Distance from 52-week high-55.31%-95.28%
Analyst consensusstrong_buybuy
Avg. price target upside+296.31%+1245.91%
Average volume282.29K1.01M
Shares outstanding34.76M54.81M
Employees475
SectorHealth CareHealth Care
IndustryBiotechnology: Pharmaceutical PreparationsBiotechnology: Pharmaceutical Preparations

Highlighted cells mark the higher value for growth, returns, margins and yield, and the lower value for P/E ratios. Highlighting is a mechanical comparison, not a recommendation.

Key differences

  • ANIX has outperformed UPB by 50.0 percentage points over the past year.

About Anixa Biosciences

ANIX stock →

Anixa Biosciences, Inc., a biotechnology company, develops therapies and vaccines that are focused on critical unmet needs in oncology. Its therapeutics programs comprising the development of liraltagene autoleucel, a chimeric endocrine receptor-T cell therapy, a novel form of chimeric antigen receptor-T cell (CAR-T) technology that is focused on treating ovarian cancer.

Health Care · Biotechnology: Pharmaceutical Preparations · 4 employees

About Upstream Bio

UPB stock →

Upstream Bio, Inc., a clinical-stage biotechnology company, develops treatments for inflammatory diseases focusing on severe respiratory disorders. It offers verekitug, which is in Phase 2 trials for the treatment of severe asthma and chronic rhinosinusitis with nasal polyps and chronic obstructive pulmonary disease and in Phase I clinical trial for treating chronic obstructive pulmonary disease.

Health Care · Biotechnology: Pharmaceutical Preparations · 75 employees

ANIX vs UPB FAQ

Which is bigger, Anixa Biosciences or Upstream Bio?

Upstream Bio (UPB) is larger, with a market capitalization of $87.15M compared with $84.82M for Anixa Biosciences (ANIX).

Which stock has performed better over the past year, ANIX or UPB?

ANIX returned -43.78% over the past 12 months, compared with -93.78% for UPB (price return, excluding dividends). Past performance does not predict future results.

Are Anixa Biosciences and Upstream Bio in the same industry?

Yes. Both are classified in the Biotechnology: Pharmaceutical Preparations industry within the Health Care sector.

More comparisons